Urologic Oncology Branch, National Cancer Institute, Center for Cancer Research, Bethesda, MD 20892, USA.
Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Cell Rep. 2018 Apr 3;23(1):313-326.e5. doi: 10.1016/j.celrep.2018.03.075.
Renal cell carcinoma (RCC) is not a single disease, but several histologically defined cancers with different genetic drivers, clinical courses, and therapeutic responses. The current study evaluated 843 RCC from the three major histologic subtypes, including 488 clear cell RCC, 274 papillary RCC, and 81 chromophobe RCC. Comprehensive genomic and phenotypic analysis of the RCC subtypes reveals distinctive features of each subtype that provide the foundation for the development of subtype-specific therapeutic and management strategies for patients affected with these cancers. Somatic alteration of BAP1, PBRM1, and PTEN and altered metabolic pathways correlated with subtype-specific decreased survival, while CDKN2A alteration, increased DNA hypermethylation, and increases in the immune-related Th2 gene expression signature correlated with decreased survival within all major histologic subtypes. CIMP-RCC demonstrated an increased immune signature, and a uniform and distinct metabolic expression pattern identified a subset of metabolically divergent (MD) ChRCC that associated with extremely poor survival.
肾细胞癌 (RCC) 不是一种单一的疾病,而是几种组织学定义的癌症,具有不同的遗传驱动因素、临床过程和治疗反应。本研究评估了来自三种主要组织学亚型的 843 例 RCC,包括 488 例透明细胞 RCC、274 例乳头状 RCC 和 81 例嫌色细胞 RCC。对 RCC 亚型的综合基因组和表型分析揭示了每个亚型的独特特征,为针对受这些癌症影响的患者制定特定于亚型的治疗和管理策略奠定了基础。BAP1、PBRM1 和 PTEN 的体细胞改变以及与亚型特异性降低生存率相关的代谢途径改变,而 CDKN2A 改变、DNA 高甲基化增加以及与所有主要组织学亚型中降低生存率相关的免疫相关 Th2 基因表达特征增加。CIMP-RCC 表现出增加的免疫特征,并且一致且独特的代谢表达模式确定了代谢差异 (MD) ChRCC 的一个亚组,与极差的生存相关。